EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The use of antibiotic, probiotic, and fecal microbiota transplantation in modulating immunotherapy efficacy and survival: a systematic review and meta-analysis of clinical outcomes

Zijun Zhai, Shuling Ma, Shijie Shang, Xinyi Liang, Shan Yin, Haofeng Lin, Rui Ding, Aimin Jiang, Ran Zhang, Meng Wu, Jinming Yu, Qian Song und 1 weitere

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag264 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Oncologist, online erschienen am 10.07.2026. Verfasst von Zijun Zhai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cheeloo College of Medicine, Shandong University Cancer Center, Jinan, 250000, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Fecal Microbiota Transplantation, Immunotherapy, Neoplasms. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have been one of the important therapeutic approaches for patients with advanced malignancies; nevertheless, their clinical efficacy remains limited in many patients. Recently, the contribution of intestinal microbiota to improved antitumor immune responses has gradually been recognized.

Methods

A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library to identify relevant studies published up to June 15, 2026. We evaluated the influence of microbiota interventions with respect to efficacy and survival in cancer patients receiving ICIs from 3 perspectives: antibiotics, probiotics, and fecal microbiota transplantation (FMT). The main endpoint was objective response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS).

Results

The final analysis comprised 106 studies, which were categorized into 3 groups: antibiotics (76 studies), probiotics (15 studies), and FMT (15 studies). Antibiotic use was correlated with compromised immunotherapy efficacy and unfavorable survival outcomes. In particular, antibiotic exposure was linked to a reduced ORR (odds ratio [OR] = 0.60, 95% CI, 0.46-0.77, P < .001), shorter OS (hazard ratio [HR] = 1.56, 95% CI, 1.44-1.69, P < .001), and shorter PFS (HR = 1.50, 95% CI, 1.32-1.70, P < .001). In contrast, probiotics showed a supportive and positive effect on immunotherapy outcomes, with improved ORR (OR = 1.95, 95% CI, 1.46-2.62, P < .001) and better OS (HR = 0.56, 95% CI, 0.41-0.78, P < .001) and PFS (HR = 0.53, 95% CI= 0.38-0.74, P < .001). FMT combined with immunotherapy achieved a favorable ORR of 0.30 (95% CI, 0.16-0.45, P < .001).

Conclusions

This meta-analysis synthesized evidence from studies on antibiotics, probiotics, and FMT use, suggesting gut microbiota offering potential approaches to enhance immunotherapy treatment effectiveness and clinical efficacy in individuals with advanced-stage solid cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsFecal Microbiota TransplantationImmunotherapyNeoplasmsProbioticsHumansTreatment Outcome

Stichwörter der Autor:innen

antibioticfecal microbiota transplantationimmune checkpoint inhibitorsmicrobiotaprobiotic

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Cheeloo College of Medicine, Shandong University Cancer Center, Jinan, 250000, China.
  • Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430023, China.
  • Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.

ORCID-Profile: Dawei Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhai, Z., Ma, S., Shang, S., Liang, X., Yin, S., Lin, H., Ding, R., Jiang, A., Zhang, R., Wu, M., Yu, J., Song, Q., & Chen, D. (2026). The use of antibiotic, probiotic, and fecal microbiota transplantation in modulating immunotherapy efficacy and survival: a systematic review and meta-analysis of clinical outcomes. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag264

Vancouver

Zhai Z, Ma S, Shang S, Liang X, Yin S, Lin H, et al. The use of antibiotic, probiotic, and fecal microbiota transplantation in modulating immunotherapy efficacy and survival: a systematic review and meta-analysis of clinical outcomes. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag264

BibTeX
@article{Zhai2026,
  author = {Zhai, Zijun and Ma, Shuling and Shang, Shijie and Liang, Xinyi and Yin, Shan and Lin, Haofeng and Ding, Rui and Jiang, Aimin and Zhang, Ran and Wu, Meng and Yu, Jinming and Song, Qian and Chen, Dawei},
  title = {The use of antibiotic, probiotic, and fecal microbiota transplantation in modulating immunotherapy efficacy and survival: a systematic review and meta-analysis of clinical outcomes},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag264}
}
Kostenlos starten →